KartRider: Drift Racing Into Second Closed Beta on June 3!
14.5.2020 06:00:00 EEST | Business Wire | Press release
The highly-anticipated free to play kart racing game, KartRider: Drift, will hold its second Closed Beta starting June 3, 2020 via the Nexon Launcher, Steam, and Xbox One, including Xbox One X delivering cross-platform play. Players can register here for a chance to join the second Closed Beta starting today!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005906/en/
KartRider: Drift Closed Beta 2 Key Art (Graphic: Business Wire)
Players invited to the second Closed Beta will receive an acceptance email, and they can pre-download the game starting on June 1, 2020 at 7 p.m. PDT. Players who participated in the first Closed Beta will automatically be included.
During the Closed Beta period, players will be introduced to a new character — Diz, as well as new skins for existing characters, plus additional karts and tracks. The Closed Beta will also showcase new functions such as Racing Pass and a new Racing School single-player mode, where new and experienced players can improve their racing skills.
Customization will be a huge part of this Closed Beta with the preview of the new wraps, which allows racers to paint their karts and create unique designs for maximum personalization. Participants will also have access to kart upgrades including choice of license plate and can decorate their karts with a lineup of new accessory balloons and character emotes.
Players will also see a revamped User Interface with a new HUD and contextual rear view mirror. The matchmaking experience has also been improved as players will be queued based on their performance in the tutorial. Driving physics of the game have also been improved since the first Closed Beta for a better racing experience.
To reward players who log in during the Closed Beta, special login rewards including a Turbo Tortoise Kart, Bunny Buggy Kart, Simian Scrapper Kart, and Deuce Coupe Kart will be unlocked. All Beta participants will also receive a White Cloud Balloon item at official launch.
Players who sign up for Closed Beta 2 at www.kartriderdrift.net will be in for a treat as KartRider: Drift has partnered with HyperX, ViewSonic and DXRacer, for an opportunity to win exclusive prizes.
KartRider: Drift’s Closed Beta will be available worldwide on the Nexon Launcher, Steam, Xbox One, including Xbox One X, with the exception of Japan, and China on console. To see a full list of available regions, please follow this link.
For more information on KartRider: Drift, visit www.kartriderdrift.net or follow @KartRiderDrift on Twitter for the latest updates and information on contests and giveaways.
Social Media: Facebook / Twitter / Instagram / Discord / Official Site
Press Assets:
About KartRider: Drift http://kartrider.nexon.net/
Launched in 2004, KartRider is a massively popular multiplayer racing franchise that boasts more than 300 million PC players. Making its debut to western audiences, KartRider: Drift takes inspiration from earlier iterations of the game, delivering competitive drift-fueled racing action, featuring different game modes, and deep character + kart customization. Available completely for free on PC Steam, Xbox One, including Xbox One X, and Nexon Launcher (PC), KartRider: Drift offers cross-platform capabilities to challenge friends regardless of the platform they choose or where they are in the world.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005906/en/
Contact information
Nexon America
Cynthia Lezama
clezama@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 09:03:00 EEST | Press release
Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial network that connects banks, telcos, payment and liquidity providers to enable settlement across international markets. Fasset will also increase investment in agentic AI-enabled systems supporting corridor banking, stablecoin settlement and tokenized asset infrastructure. After raising Series B in May, Fasset has now raised a total of $119 million in 2026. The financing marks Fasset’s entry into the glob
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 08:11:00 EEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 02:01:00 EEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom